Please select the option that best describes you:

Which BRAF/MEK inhibitor combination have you found most tolerable and easiest to prescribe in good performance patients with mutated metastatic melanoma?  

What would be your approach while deciding among the various combinations available?



Answer from: Medical Oncologist at Academic Institution

Answer from: Medical Oncologist at Academic Institution